Canada markets open in 7 hours 2 minutes

Affimed N.V. (A28.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
3.1060-0.0490 (-1.55%)
As of 08:02AM CEST. Market open.
Full screen
Previous Close3.1550
Open3.1550
Bid3.1065 x 100000
Ask3.2285 x 100000
Day's Range3.1060 - 3.1060
52 Week Range2.1285 - 6.3500
Volume31
Avg. Volume1,499
Market Cap480.163M
Beta (5Y Monthly)2.31
PE Ratio (TTM)N/A
EPS (TTM)-0.6260
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.79
  • GlobeNewswire

    Affimed to Report Second Quarter 2022 Financial Results & Corporate Update on August 11, 2022

    HEIDELBERG, Germany, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2022 results and corporate update on Thursday, August 11, 2022. The Company will host a conference call at 8:30 a.m. Eastern Daylight Time. The conference call will be available via phone and webcast. To access the call,

  • Simply Wall St.

    Affimed (NASDAQ:AFMD) shareholders have endured a 57% loss from investing in the stock a year ago

    Affimed N.V. ( NASDAQ:AFMD ) shareholders should be happy to see the share price up 14% in the last month. But that...

  • GlobeNewswire

    Affimed Establishes Scientific Advisory Board

    Independent advisory panel to be made up of distinguished, key opinion leaders with scientific and clinical expertise in innate immunity and oncologyScientific Advisory Board to provide guidance on the Company’s development strategy across assets and assessment of emerging technologies HEIDELBERG, Germany, June 30, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to